The application of biomarker assays for evaluating ovarian masses in our local setting is secondary to ultrasound, but adopting multivariate index assays rather than CA-125 for adjunct testing would increase the detection of early-stage ovarian cancers regardless of menopausal status. The gene discussed is MUC16; the disease is ovarian cancer.